Regulatory barriers limit clinical trials of medical cannabis in the United States. Longitudinal cohort studies may be one feasible alternative that could yield clinically relevant information. Willingness to participate in such studies is not known.
Materials and Methods:
In October 2016, we surveyed a convenience sample of patients with chronic pain from two New York registered organizations (responsible for growing, processing, distributing, and retailing medical cannabis products). After a vignette describing a longitudinal cohort study involving weekly patient-reported outcomes and quarterly assessments of physical functioning and urine and blood tests, we asked about respondents' willingness to participate. We examined willingness to participate, duration of participation, and frequency of data collections overall and by subgroups, using multivariable logistic regression models.
Results:
Of 405 respondents (estimated response rate: 30%), 54% were women and 81% were white non-Hispanic. Neuropathy was the most common pain condition (67%) followed by inflammatory bowel disease (19%). Of respondents, 94% (95% CI 92–97%) thought that the study should be done, 85% (95% CI 81–88%) would definitely or probably enroll if asked, 76% (95% CI 72–81%) would participate for ≥1 year, and 59% (95% CI 54–64%) would respond to questions at least daily. Older age was the only factor associated with lower willingness to participate, lower willingness to participate for ≥1 year, and lower willingness to respond to questions at least daily.
Conclusions:
Nearly all respondents were supportive of the proposed study and most reported that they would enroll if asked. Enhanced engagement with older individuals may be needed to promote equal enrollment. Recruitment for longitudinal cohort studies with frequent data collection appears feasible in this patient population.
Get full access to this article
View all access options for this article.
References
1.
GuyGPJr., ZhangK, BohmMK, et al.Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017; 66:697–704.
2.
RuddRA, SethP, DavidF, et al.Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016; 65:1445–1452.
3.
National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: current state of evidence and recommendations for research. Washington, DC: The National Academies Press, 2017.
AbramsDI, JayCA, ShadeSB, et al.Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007; 68:515–521.
6.
EllisRJ, ToperoffW, VaidaF, et al.Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34:672–680.
7.
WallaceMS, MarcotteTD, UmlaufA, et al.Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015; 16:616–627.
WilseyB, MarcotteT, TsodikovA, et al.A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008; 9:506–521.
10.
NoyesRJr., BrunkSF, AveryDA, et al.The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975; 18:84–89.
11.
CruiseCE, BroderickJ, PorterL, et al.Reactive effects of diary self-assessment in chronic pain patients. Pain. 1996; 67:253–258.
12.
von BaeyerCL. Reactive effects of measurement of pain. Clin J Pain. 1994; 10:18–21.
13.
RobinsJM, HernanMA, BrumbackB. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11:550–560.
14.
RyanJ, Sharts-HopkoN. The experiences of medical marijuana patients: a scoping review of the qualitative literature. J Neurosci Nurs. 2017; 49:185–190.
15.
SatterlundTD, LeeJP, MooreRS. Stigma among California's medical marijuana patients. J Psychoactive Drugs. 2015; 47:10–17.
16.
New York State Department of Health. Medical use of marijuana under the Compassionate Care Act: two-year report. Albany, NY: New York State Department of Health, 2016.
17.
CasarettD, KarlawishJ, SankarP, et al.Obtaining informed consent for clinical pain research: patients' concerns and information needs. Pain. 2001; 92:71–79.
18.
CasarettD, KarlawishJ, SankarP, et al.Obtaining informed consent for cancer pain research: do patients with advanced cancer and patients with chronic pain have different concerns?. J Pain Symptom Manage. 2002; 24:506–516.
19.
KaufmanDJ, BakerR, MilnerLC, et al.A survey of U.S adults' opinions about conduct of a nationwide precision medicine initiative(R) cohort study of genes and environment. PLoS One. 2016; 11:e0160461.
20.
SandersonSC, BrothersKB, MercaldoND, et al.Public attitudes toward consent and data sharing in Biobank Research: a large multi-site experimental survey in the US. Am J Hum Genet. 2017; 100:414–427.
21.
RahmAK, WrennM, CarrollNM, et al.Biobanking for research: a survey of patient population attitudes and understanding. J Community Genet. 2013; 4:445–450.
22.
HorchJD, CarrEC, HarasymP, et al.Firefighter willingness to participate in a stem cell clinical trial for burns: a mixed methods study. Burns. 2016; 42:1740–1750.
23.
MaoJJ, TanT, LiSQ, et al.Attitudes and barriers towards participation in an acupuncture trial among breast cancer patients: a survey study. BMC Complement Altern Med. 2014; 14:7.
24.
KaplanCP, NapolesAM, NarineS, et al.Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015; 45:443–448.
25.
GeppertC, CandilisP, BakerS, et al.Motivations of patients with diabetes to participate in research. AJOB Empir Bioeth. 2014; 5:14–21.
26.
SlegersC, ZionD, GlassD, et al.Why do people participate in epidemiological research?. J Bioeth Inq. 2015; 12:227–237.
27.
LocockL, SmithL. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials. Clin Trials. 2011; 8:85–93.
28.
WalkerER, NelsonCR, Antoine-LaVigneD, et al.Research participants' opinions on genetic research and reasons for participation: a Jackson Heart Study focus group analysis. Ethn Dis. 2014; 24:290–297.
29.
RobinsonJO, CarrollTM, FeuermanLZ, et al.Participants and study decliners' perspectives about the risks of participating in a clinical trial of whole genome sequencing. J Empir Res Hum Res Ethics. 2016; 11:21–30.
30.
DubeK, EvansD, SyllaL, et al.Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US. J Virus Erad. 2017; 3:40–50.e21.
31.
JamesDC, HarvilleC2nd. Barriers and motivators to participating in mHealth research among African American men. Am J Mens Health. 2017; 11:1605–1613.
32.
JamesDC, HarvilleC2nd, WhiteheadN, et al.Willingness of African American women to participate in e-Health/m-Health research. Telemed J E Health. 2016; 22:191–197.
33.
MoorcraftSY, MarriottC, PeckittC, et al.Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016; 17:1–7.
34.
SpearsCR, SandbergJC, O'NeillJL, et al.Recruiting underserved mothers to medical research: findings from North Carolina. J Health Care Poor Underserved. 2013; 24:1801–1815.
35.
ByrneMM, TannenbaumSL, GluckS, et al.Participation in cancer clinical trials: why are patients not participating?. Med Decis Making. 2014; 34:116–126.
36.
KratzAL, KalpakjianCZ, HanksRA. Are intensive data collection methods in pain research feasible in those with physical disability? A study in persons with chronic pain and spinal cord injury. Qual Life Res. 2017; 26:587–600.
37.
SterlingR, HendersonGE, Corbie-SmithG. Public willingness to participate in and public opinions about genetic variation research: a review of the literature. Am J Public Health. 2006; 96:1971–1978.
38.
EllisPM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol. 2000; 11:939–945.
39.
KrebsEE, LorenzKA, BairMJ, et al.Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009; 24:733–738.
40.
KroenkeK, TheobaldD, WuJ, et al.Comparative responsiveness of pain measures in cancer patients. J Pain. 2012; 13:764–772.
41.
WhiteIR, RoystonP, WoodAM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011; 30:377–399.
42.
LanfearDE, JonesPG, CresciS, et al.Factors influencing patient willingness to participate in genetic research after a myocardial infarction. Genome Med. 2011; 3:3–9.
43.
CottlerLB, McCloskeyDJ, Aguilar-GaxiolaS, et al.Community needs, concerns, and perceptions about health research: findings from the clinical and translational science award sentinel network. Am J Public Health. 2013; 103:1685–1692.
44.
UhlmannS, MilloyMJ, AhamadK, et al.Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs. Am J Addict. 2015; 24:368–373.
45.
KerathSM, KleinG, KernM, et al.Beliefs and attitudes towards participating in genetic research—a population based cross-sectional study. BMC Public Health. 2013; 13:11–4.
46.
GreenBB, AndersonML, RalstonJD, et al.Patient ability and willingness to participate in a web-based intervention to improve hypertension control. J Med Internet Res. 2011; 13:e–1.
47.
BrooksEA, UnruhA, LynchME. Exploring the lived experience of adults using prescription opioids to manage chronic noncancer pain. Pain Res Manag. 2015; 20:15–22.
48.
SimmondsMJ, FinleyEP, ValeS, et al.A qualitative study of veterans on long-term opioid analgesics: barriers and facilitators to multimodality pain management. Pain Med. 2015; 16:726–732.
49.
HoweCQ, SullivanMD, SaundersKW, et al.Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. Clin J Pain. 2012; 28:561–566.
50.
CasarettD, KarlawishJ, SankarP, et al.Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain?. Pain Med. 2001; 2:309–316.
51.
ZallerN, TopletzA, FraterS, et al.Profiles of medicinal cannabis patients attending compassion centers in Rhode island. J Psychoactive Drugs. 2015; 47:18–23.
52.
LucasP. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012; 44:125–133.
53.
PiperBJ, DeKeusterRM, BealsML, et al.Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017:31:569–575.
54.
BoehnkeKF, LitinasE, ClauwDJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016; 17:739–744.
55.
ReimanA, WeltyM, SolomonP. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017; 2:160–166.
56.
LucasP, WalshZ. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017; 42:30–35.
57.
VigilJM, StithSS, AdamsIM, et al.Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PLoS One. 2017; 12:e018779–5.
58.
CorroonJMJr., MischleyLK, SextonM. Cannabis as a substitute for prescription drugs—a cross-sectional study. J Pain Res. 2017; 10:989–998.
59.
SextonM, CuttlerC, FinnellJS, et al.A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016; 1:131–138.
60.
BachhuberMA, SalonerB, CunninghamCO, et al.Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014; 174:1668–1673.
61.
BradfordAC, BradfordWD. Medical marijuana laws reduce prescription medication use in Medicare part D. Health Aff (Millwood). 2016; 35:1230–1236.
62.
BradfordAC, BradfordWD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff (Millwood). 2017; 36:945–951.
63.
StuchlikP, ZhangX, GavinS, et al.Willingness to participate in cardiovascular clinical research among African-Americans. J Clin Res Bioeth. 2015; 6:pii:223.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
